Liu Pharmaceutical Group (603368.SH) released its 2023 annual performance report. The company's total revenue was 208.12...
According to Zhitong Finance App News, Liuyao Group (603368.SH) released its 2023 annual performance report. The company's total revenue was 20.812 billion yuan, up 9.23% year on year; net profit attributable to shareholders of listed companies was 847 million yuan, up 20.70% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 834 million yuan, up 20.01% year on year; basic earnings per share were 2.34 yuan.
The company's business performance continued to grow steadily in 2023. The main reason is that the company closely focuses on established performance goals and development plans, and leverages the advantages of batch and zero collaboration, industrial and commercial collaboration, and pharmaceutical device collaboration to promote the transformation and growth of traditional wholesale and retail businesses and the expansion and strengthening of the industrial sector. In the pharmaceutical wholesale sector, the company strengthens supplier cooperation, seizes high-quality new products, actively expands SPD projects for pharmaceutical consumables, promotes the implementation of the collection and distribution model, and steadily increases the size of the wholesale market, especially the market share of equipment consumables. In the pharmaceutical retail sector, the company continues to expand the retail store layout, optimize the variety structure, develop professional innovative businesses such as prescription outreach, chronic disease management, and DTP, and promote the quality and profit of the retail business. In the pharmaceutical industry sector, the company has steadily increased the scale of industrial production capacity, continuously enriched products, integrated commercial channel resources, and continued to expand markets outside the region while speeding up the coverage of the Guangxi market. The revenue and net profit of the industrial sector continued to grow rapidly, and its profit contribution to the company continued to expand, becoming a new profit growth point for the company. The company's traditional Chinese medicine formula granule project has completed the filing of more than 450 varieties. Customer development continues to accelerate, becoming a new business increase, laying the foundation for future performance growth.